This story is unavailable.

I empathize with your condition and I agree we have to make sure chronic illnesses get treated or even cured. However, I also see a problem with the prices of the bio drugs. It’s fine to have patent protection and charge all you can for the lifetime of that patent. But in the case of enbrel (a cousin of humira at similar or higher cost), the patent was extended right when it was about to expire by another 17 years. I don’t quite understand how this is constitutionally possible, but that’s what happened. There are biosimilars in Korea and India (and perhaps some other places) that cost a fraction of the originals. I agree that for sufferers those bio drugs are worth every penny, but we also have to consider that they are a cause for the explosion in health care costs, making insurance unaffordable for many even under Obamacare. For health care to become affordable, we need reform in drug pricing, limitations in liability for physicians and hospitals, and we have to question why we can’t have a public option (i.e. not-for-profit insurance). Finally, there are still some extreme salaries in some areas in the medical field, like multi-million dollar salaries in non-profit hospitals that I don’t quite understand, much of it going to administrators. None of this was addressed by Obama, who wanted to make nice with every single lobby. I am not saying it would have been easy, but taking the public option off the table didn’t really help his negotiating position with big pharma, insurance, and medical lobbies.

Like what you read? Give Martin Burkhardt a round of applause.

From a quick cheer to a standing ovation, clap to show how much you enjoyed this story.